Literature DB >> 17079284

Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9.

Andreas Pichlmair1, Sandra S Diebold, Stephen Gschmeissner, Yasuhiro Takeuchi, Yasuhiro Ikeda, Mary K Collins, Caetano Reis e Sousa.   

Abstract

Recombinant lentiviral vectors (LVs) are commonly used as research tools and are being tested in the clinic as delivery agents for gene therapy. Here, we show that Vesicular stomatitis virus G protein (VSV-G)-pseudotyped LV preparations produced by transient transfection are heavily contaminated with tubulovesicular structures (TVS) of cellular origin, which carry nucleic acids, including the DNA plasmids originally used for LV generation. The DNA carried by TVS can act as a stimulus for innate antiviral responses, triggering Toll-like receptor 9 and inducing alpha/beta interferon production by plasmacytoid dendritic cells (pDC). Removal of TVS markedly reduces the ability of VSV-G-pseudotyped LV preparations to activate pDC. Conversely, virus-free TVS are sufficient to stimulate pDC and act as potent adjuvants in vivo, eliciting T- and B-cell responses to coadministered proteins. These results highlight the role of by-products of virus production in determining the immunostimulatory properties of recombinant virus preparations and suggest possible strategies for diminishing responses to LVs in gene therapy and in research use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079284      PMCID: PMC1797478          DOI: 10.1128/JVI.01818-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response.

Authors:  Michael J Palmowski; Luciene Lopes; Yasuhiro Ikeda; Mariolina Salio; Vincenzo Cerundolo; Mary K Collins
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

Review 2.  HIV-1 vectors: fulfillment of expectations, further advancements, and still a way to go.

Authors:  Adam S Cockrell; Tal Kafri
Journal:  Curr HIV Res       Date:  2003-10       Impact factor: 1.581

3.  Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment.

Authors:  Lakshmi Sastry; Yi Xu; Ryan Cooper; Karen Pollok; Kenneth Cornetta
Journal:  Hum Gene Ther       Date:  2004-02       Impact factor: 5.695

Review 4.  IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors.

Authors:  Yong-Jun Liu
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

5.  Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction.

Authors:  Kenya Honda; Yusuke Ohba; Hideyuki Yanai; Hideo Negishi; Tatsuaki Mizutani; Akinori Takaoka; Choji Taya; Tadatsugu Taniguchi
Journal:  Nature       Date:  2005-04-06       Impact factor: 49.962

Review 6.  Type I interferons (alpha/beta) in immunity and autoimmunity.

Authors:  Argyrios N Theofilopoulos; Roberto Baccala; Bruce Beutler; Dwight H Kono
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

7.  Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA.

Authors:  Sandra S Diebold; Tsuneyasu Kaisho; Hiroaki Hemmi; Shizuo Akira; Caetano Reis e Sousa
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

8.  Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8.

Authors:  Florian Heil; Hiroaki Hemmi; Hubertus Hochrein; Franziska Ampenberger; Carsten Kirschning; Shizuo Akira; Grayson Lipford; Hermann Wagner; Stefan Bauer
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

9.  Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9.

Authors:  Anne Krug; Gary D Luker; Winfried Barchet; David A Leib; Shizuo Akira; Marco Colonna
Journal:  Blood       Date:  2003-10-16       Impact factor: 22.113

10.  Quantitation of HLA class II protein incorporated into human immunodeficiency type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles.

Authors:  Charles M Trubey; Elena Chertova; Lori V Coren; Joanne M Hilburn; Catherine V Hixson; Kunio Nagashima; Jeffrey D Lifson; David E Ott
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  34 in total

1.  Characterization of retroviral and lentiviral vectors pseudotyped with xenotropic murine leukemia virus-related virus envelope glycoprotein.

Authors:  Toshie Sakuma; Suk See De Ravin; Jason M Tonne; Tayaramma Thatava; Seiga Ohmine; Yasuhiro Takeuchi; Harry L Malech; Yasuhiro Ikeda
Journal:  Hum Gene Ther       Date:  2010-09-17       Impact factor: 5.695

2.  Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation.

Authors:  Jocelyn T Kim; Yarong Liu; Rajan P Kulkarni; Kevin K Lee; Bingbing Dai; Geoffrey Lovely; Yong Ouyang; Pin Wang; Lili Yang; David Baltimore
Journal:  Sci Immunol       Date:  2017-07-21

3.  Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.

Authors:  Osvaldo Martinez; Lee Tantral; Nirupama Mulherkar; Kartik Chandran; Christopher F Basler
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

4.  Advances in Overcoming Immune Responses following Hemophilia Gene Therapy.

Authors:  Carol H Miao
Journal:  J Genet Syndr Gene Ther       Date:  2011-12-23

5.  Sensing of HIV-1 Entry Triggers a Type I Interferon Response in Human Primary Macrophages.

Authors:  Jérémie Decalf; Marion Desdouits; Vasco Rodrigues; François-Xavier Gobert; Matteo Gentili; Santy Marques-Ladeira; Célia Chamontin; Marylène Mougel; Bruna Cunha de Alencar; Philippe Benaroch
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

6.  Mutations in human immunodeficiency virus type 1 nucleocapsid protein zinc fingers cause premature reverse transcription.

Authors:  James A Thomas; William J Bosche; Teresa L Shatzer; Donald G Johnson; Robert J Gorelick
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

Review 7.  Progress and prospects: immune responses to viral vectors.

Authors:  S Nayak; R W Herzog
Journal:  Gene Ther       Date:  2009-11-12       Impact factor: 5.250

8.  Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses.

Authors:  Luciene Lopes; Marie Dewannieux; Uzi Gileadi; Ranbir Bailey; Yasuhiro Ikeda; Christopher Whittaker; Matthew P Collin; Vincenzo Cerundolo; Mizuki Tomihari; Kiyoshi Ariizumi; Mary K Collins
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

9.  The immunomodulatory role of Regnase family RNA-binding proteins.

Authors:  Maximilian Fischer; Tobias Weinberger; Christian Schulz
Journal:  RNA Biol       Date:  2020-08-05       Impact factor: 4.652

10.  Lentiviral vector-based prime/boost vaccination against AIDS: pilot study shows protection against Simian immunodeficiency virus SIVmac251 challenge in macaques.

Authors:  Anne-Sophie Beignon; Karine Mollier; Christelle Liard; Frédéric Coutant; Sandie Munier; Julie Rivière; Philippe Souque; Pierre Charneau
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.